Skip to main content

Advertisement

SpringerLink
Log in

Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours

  • Review Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Somatostatin receptors are over-expressed in many tumours, mainly of neuroendocrine origin, thus enabling treatment with somatostatin analogues. Almost a decade of clinical experience of receptor radionuclide therapy with the analogue 90Y-[DOTA]0-Tyr3-octreotide [90Y-DOTATOC] has now been obtained at a few centres of excellence. This review reports on the present state of the art of receptor radionuclide therapy and discusses new perspectives.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1a, b
Fig. 2a–c
Fig. 3a–d

Similar content being viewed by others

References

  1. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179(68):77–9

    Google Scholar 

  2. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB. Mini review: the somatostatin receptor family. Life Sci 1995;57:1249–65

    CAS  PubMed  Google Scholar 

  3. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Macke HR. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27(3):273–82

    Google Scholar 

  4. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28(7):836–46

    Google Scholar 

  5. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996;334(4):246–54

  6. Hejna M, Schmidinger M, Raderer M. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol 2002;13:653–68

    Article  PubMed  Google Scholar 

  7. Di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, Zilembo N, Di Leo A. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 1996;77(2):402–8

    Google Scholar 

  8. Eriksson B, Renstrup J, Imam H, Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 1997;8(10):1041–4

    Google Scholar 

  9. Bontenbal M, Foekens JA, Lamberts SW, et al. Feasibility, endocrine and anti-tumor effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up. Br J Cancer 1998;77:115–22

    CAS  PubMed  Google Scholar 

  10. O’Byrne KJ, Dobbs N, Propper DJ, et al. Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer. Br J Cancer 1999;79:1413–8

    Article  CAS  PubMed  Google Scholar 

  11. Macauley VM, Smith IE, Everard MJ, et al. Experimental and clinical studies with somatostatin analogue octreotide in small-cell lung cancer. Br J Cancer 1991;64:451–6

    PubMed  Google Scholar 

  12. Marschke RF Jr, Grill JP, Sloan JA, et al. Phase II study of high-dose somatostatin analogue in patients either previously treated or untreated who have extensive-stage small cell lung cancer. Am J Clin Oncol 1999;22:15–7

    Article  PubMed  Google Scholar 

  13. Figg WD, Thibault A, Cooper MR, et al. A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer. Cancer 1995;75:2159–64

    CAS  PubMed  Google Scholar 

  14. Di Leo A, Bajetta E, Ferrari L, et al. A dose-finding study of lanreotide (a somatostatin analogue) in patients with colorectal carcinoma. Cancer 1996;78:35–42

    Article  CAS  PubMed  Google Scholar 

  15. Friess H, Buchler M, Beglnger C, et al. Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas 1993;8:540–5

    CAS  PubMed  Google Scholar 

  16. Krenning EP, Kwekkeboom DJ, Bakker WH et al. Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]-octreotide and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20(8):716–31

    Google Scholar 

  17. Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, De Jong FH, Christiansen A, Kam BL, De Herder WW, Stridsberg M, Lindemans J, Ensing G, Krenning EP. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]-octreotide: the Rotterdam experience. Semin Nucl Med 2002;32(2):110–22

  18. de Jong M, Bakker WH, Breeman WA et al. Pre-clinical comparison of [DTPA0, Tyr3]octreotide and [DOTA0, d-Phe1, Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Int J Cancer 1998;75:406–11

    Article  PubMed  Google Scholar 

  19. Cremonesi M, Ferrari M, Zoboli S, Chinol M, Stabin MG, Orsi F, Maecke HR, Jermann E, Robertson C, Fiorenza M, Tosi G, Paganelli G. Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide: implications for internal radiotherapy with 90Y-DOTATOC. Eur J Nucl Med 1999;26(8):877–86

    Google Scholar 

  20. Cremonesi M, Bodei M, Rocca P, Stabin M, Maecke H, Paganelli G. Kidney protection during receptor-mediated radiotherapy with 90Y-[DOTA0, Tyr3]octreotide. Cancer Biother Radiopharm 2002;17(3):344

    Google Scholar 

  21. Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, de Camps J, Schran H, Chen T, Smith MC, Bouterfa H, Valkema R, Krenning EP, Kvols LK, Pauwels S. 86Y-DOTA0)-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003;30(4):510–8

    Google Scholar 

  22. National Council on Radiation Protection and Measurements. Misadministration of radioactive material in medicine—scientific background. Bethesda, MD 1991:27

  23. Bodei L, Chinol M, Cremonesi M, Paganelli G. Facts and myths about radiopeptide therapy: Scylla, Charybdis and Sibyl. Eur J Nucl Med 2002;29:1099–100

    Article  Google Scholar 

  24. Boerman OC, Oyen WJ, Corstens FH. Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. Eur J Nucl Med 2001;28(10):1447–9

    Google Scholar 

  25. Behr TM, Behe M, Kluge G, Gotthardt M, Schipper ML, Gratz S, Arnold R, Becker W, Goldenberg DM. Nephrotoxicity vs anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis. Eur J Nucl Med Mol Imaging 2002;29(2):277–9

    Google Scholar 

  26. Cybulla M, Weiner SM, Otte A. End-stage renal disease after treatment with 90Y-DOTATOC. Eur J Nucl Med 2001;28:1552–4

    CAS  PubMed  Google Scholar 

  27. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, Maecke HR, Muller J. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999;26(11):1439–47

    Google Scholar 

  28. de Jong M, Krenning EP. New advances in peptide receptor radionuclide therapy. J Nucl Med 2002;43(5):617–20

    Google Scholar 

  29. Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, Caracciolo M, Macke HR, Chinol M, Paganelli G. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003;30(2):207–16

    Google Scholar 

  30. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003;30(1):9–15

    Google Scholar 

  31. Chinol M, Casalini P, Maggiolo M, Canevari S, Omodeo ES, Caliceti P, Veronese FM, Cremonesi M, Chiolerio F, Nardone E, Siccardi AG, Paganelli G. Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. Br J Cancer 1998;78(2):189–97

    Google Scholar 

  32. De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002;32(2):133–40

    Google Scholar 

  33. Paganelli G, Zoboli S, Cremonesi, Cremonesi M, Bodei L, Ferrari M, Grana C, Bartolomei M, Orsi F, De Cicco C, Maecke HR, Chinol M, de Braud F. Receptor-mediated radiotherapy with 90Y-DOTA-d-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001;28:426–34

    CAS  PubMed  Google Scholar 

  34. Chinol M, Bodei L, Cremonesi M, Paganelli G. Receptor-mediated radiotherapy with 90Y-DOTA-d-Phe1-Tyr3-octreotide: the experience of the European Institute of Oncology group. Semin Nucl Med 2002;32(2):141–47

    Google Scholar 

  35. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, Haldemann A, Mueller-Brand J. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med 2002;43(5):610–6

    Google Scholar 

  36. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJM, Kooij PPM, de Herder WW, Feelders RA, van Eijck CHJ, de Jong M, Srinivasan A, Erion JL, Krenning EP. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med 2003;30(3):417–22

    Google Scholar 

  37. Kwekkeboom DJ, Bakker WH, Teunissen JJM, Kooij PPM, Krenning EP. Treatment with Lu-177-DOTA-Tyr3-Octreotate in patients with neuroendocrine tumors: interim results. Eur J Nucl Med Mol Imaging 2003;30(2):S231

    Google Scholar 

  38. de Jong M, Kwekkeboom DJ, Valkema R, Krenning EP. Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med 2003;30:463–9

    Google Scholar 

  39. de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, Bugaj JE, Erion J, Schmidt M, Srinivasan A, Krenning EP. [177Lu-DOTA(0), Tyr3]-octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001;92(5):628–33

    Google Scholar 

  40. de Jong M, Breeman WA, Bernard BF, Bakker WH, Visser TJ, Kooij PP, van Gameren A, Krenning EP. Tumour response after [90Y-DOTA0-Tyr3]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 2001;42:1841–6

    Google Scholar 

  41. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30(5):781–93

    Google Scholar 

Download references

Acknowledgements

The authors thank Daria Handkiewicz-Junak, Maribel Lopera Sierra, Helmut R Mäcke and Filippo de Braud for their invaluable help in the preparation of this manuscript. The authors thank William Russell-Edu for his kind assistance in revising the English of this manuscript and Mrs. Deborah Console for the editing. This work was supported by grants from the Italian Association for Cancer Research (AIRC), the Italian National Council for Research (PSO CNR-MIUR) and the Italian Ministry of Health.

Author information

Authors and Affiliations

  1. Nuclear Medicine Division, European Institute of Oncology, via Ripamonti 435, 20141, Milan, Italy

    Lisa Bodei, Chiara Grana, Paola Rocca, Mirco Bartolomei, Marco Chinol & Giovanni Paganelli

  2. Medical Physics Division, European Institute of Oncology, Milan, Italy

    Marta Cremonesi

Authors
  1. Lisa Bodei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marta Cremonesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chiara Grana
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paola Rocca
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mirco Bartolomei
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marco Chinol
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Giovanni Paganelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni Paganelli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bodei, L., Cremonesi, M., Grana, C. et al. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 31, 1038–1046 (2004). https://doi.org/10.1007/s00259-004-1571-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-004-1571-4

Keywords

Search

Navigation